R. Rosell

817 total citations
21 papers, 612 citations indexed

About

R. Rosell is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, R. Rosell has authored 21 papers receiving a total of 612 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Surgery, 7 papers in Pulmonary and Respiratory Medicine and 7 papers in Oncology. Recurrent topics in R. Rosell's work include Nausea and vomiting management (5 papers), Lung Cancer Treatments and Mutations (5 papers) and Lung Cancer Research Studies (4 papers). R. Rosell is often cited by papers focused on Nausea and vomiting management (5 papers), Lung Cancer Treatments and Mutations (5 papers) and Lung Cancer Research Studies (4 papers). R. Rosell collaborates with scholars based in Spain, United States and Poland. R. Rosell's co-authors include Marianne Paesmans, Marcello Tiseo, Joan H. Schiller, Paola Mazzanti, Luca Boni, Petr Zatloukal, D. Bisset, Frank V. Fossella, Davorin Radosavljević and Adriano Paccagnella and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Annals of Oncology.

In The Last Decade

R. Rosell

19 papers receiving 596 citations

Peers

R. Rosell
S. Romito Italy
L Portalone Italy
Ruqin Chen United States
Yvonne Lassere United States
Suzanne M. Fields United States
Giuseppe De Cataldis Italy
A Krikorian France
R. Smith United States
E Piana Italy
Silvia Gasperoni Italy
S. Romito Italy
R. Rosell
Citations per year, relative to R. Rosell R. Rosell (= 1×) peers S. Romito

Countries citing papers authored by R. Rosell

Since Specialization
Citations

This map shows the geographic impact of R. Rosell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Rosell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Rosell more than expected).

Fields of papers citing papers by R. Rosell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Rosell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Rosell. The network helps show where R. Rosell may publish in the future.

Co-authorship network of co-authors of R. Rosell

This figure shows the co-authorship network connecting the top 25 collaborators of R. Rosell. A scholar is included among the top collaborators of R. Rosell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Rosell. R. Rosell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mok, Tony, Alice T. Shaw, Shirish M. Gadgeel, et al.. (2019). Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK+ NSCLC. Annals of Oncology. 30. v607–v607. 12 indexed citations
2.
Gettinger, Scott, Lyudmila Bazhenova, Ravi Salgia, et al.. (2016). 56 Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results. Lung Cancer. 91. S20–S21. 4 indexed citations
3.
Cobo, M., Bartomeu Massutí, Teresa Morán, et al.. (2008). Spanish customized adjuvant trial (SCAT) based on BRCA1 mRNA levels. Journal of Clinical Oncology. 26(15_suppl). 7533–7533. 17 indexed citations
4.
Balañá, Carmen, Cristina Carrato, Mireia Berdiel‐Acer, et al.. (2008). Concordance and clinical value of the MGMT promoter methylation pattern in tissue with paired serum and MGMT protein expression in a series of glioblastoma (GB) patients. Journal of Clinical Oncology. 26(15_suppl). 2037–2037. 1 indexed citations
5.
Font, Albert, Miguel Tarón, Céu Costa, et al.. (2008). BRCA1 mRNA expression in patients (p) with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy. Journal of Clinical Oncology. 26(15_suppl). 5021–5021. 10 indexed citations
6.
Font, Albert, J Fernández-Llamazares, J. Boix, et al.. (2007). Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer. Clinical & Translational Oncology. 9(3). 177–182. 22 indexed citations
7.
Ardizzoni, Andrea, Luca Boni, Marcello Tiseo, et al.. (2007). Cisplatin- Versus Carboplatin-Based Chemotherapy in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: An Individual Patient Data Meta-analysis. JNCI Journal of the National Cancer Institute. 99(11). 847–857. 464 indexed citations
8.
You, Lingchong, et al.. (2005). O-003 Writ inhibitory factor-1 (WIF-1) is silenced by promoter hypermethylation in human non-small cell lung cancer. Lung Cancer. 49. S5–S5. 1 indexed citations
9.
Rosell, R.. (2003). Targeted therapy in combination with gemcitabine in non-small cell lung cancer. Seminars in Oncology. 30(4 Suppl 10). 19–25. 33 indexed citations
10.
Izquierdo, Á., et al.. (2001). A phase II study of weekly docetaxel and concurrent radiation in patients (pts) with unresectable esophageal cancer. European Journal of Cancer. 37. S315–S315. 1 indexed citations
11.
Rosell, R., Ana Isabel Antón, Irene Moreno, et al.. (1994). PROGNOSTIC VALUE OF K-RAS 12 GENOTYPES IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG-CANCER RECEIVING CARBOPLATIN WITH EITHER INTRAVENOUS OR CHRONIC ORAL DOSE ETOPOSIDE. International Journal of Oncology. 5(2). 169–76. 9 indexed citations
12.
Alastrué, A, et al.. (1992). [Experience with 150 subcutaneous venous reservoirs for venous access and infusion for the treatment of adult patients with oncologic and hematologic disorders and acquired immunodeficiency syndrome].. PubMed. 99(12). 444–9. 4 indexed citations
13.
14.
15.
Rosell, R., et al.. (1990). [The description of a new cellular type, Pinocchio cells, induced during the treatment of solid tumors with interleukin-2].. PubMed. 95(12). 447–50. 1 indexed citations
16.
Díaz‐Rubio, Eduardo, et al.. (1989). Oral Idarubicin in Measurable Gastric Cancer. American Journal of Clinical Oncology. 12(1). 14–16. 7 indexed citations
17.
Rosell, R., et al.. (1989). Antiemetic Efficacy of Escalating Doses of Alizapride against Chemotherapy-Induced Emesis. Oncology. 46(4). 235–237. 1 indexed citations
18.
Rosell, R., et al.. (1986). [Evaluation of an antiemetic regimen with a high-dose metoclopramide, dexamethasone and diphenhydramine combination in chemotherapy regimens with cisplatin].. PubMed. 87(19). 796–8. 2 indexed citations
19.
Rosell, R., et al.. (1985). Evaluation of a combination antiemetic regimen including iv high-dose metoclopramide, dexamethasone, and diphenhydramine in cisplatin-based chemotherapy regimens.. PubMed. 69(7-8). 909–10. 13 indexed citations
20.
Woessner, S, R. Rosell, C Rozmán, et al.. (1977). Index autorum ad Vol. 58, 1977. Acta Haematologica. 58(6). 374–376. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by S. Romito Breakdown of academic impact, for papers by L Portalone Breakdown of academic impact, for papers by Ruqin Chen Breakdown of academic impact, for papers by Yvonne Lassere Breakdown of academic impact, for papers by Suzanne M. Fields Breakdown of academic impact, for papers by Giuseppe De Cataldis Breakdown of academic impact, for papers by A Krikorian Breakdown of academic impact, for papers by R. Smith Breakdown of academic impact, for papers by E Piana Breakdown of academic impact, for papers by Silvia Gasperoni
Rankless by CCL
2026